Saltar al contenido principal
Elsevier

Molecular and Cellular Basis of Metastasis: Road to Therapy

  • 1 Edición, Volumen 132 - 3 de septiembre de 2016
  • Última edición
  • Editores: Danny R Welch, Paul B. Fisher
  • Idioma: Inglés

Molecular and Cellular Basis of Metastasis: Road to Therapy, the latest in the Advances in Cancer Research series, provides invaluable information on the exciting and fast-moving… Leer más

Descripción

Molecular and Cellular Basis of Metastasis: Road to Therapy, the latest in the Advances in Cancer Research series, provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics, with this volume covering the molecular and cellular basis of metastasis.

Puntos claves

  • Presents groundbreaking information on the molecular and cellular basis of metastasis
  • Provides information on cancer research
  • Outstanding and original reviews
  • Suitable for both researchers and students

De interès para

Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology

Índice

1. Imaging of metastases Paul B. Fisher2. Dormancy Julio Aguirre-Ghiso3. Host genetics regulating metastasis Kent Hunter and Nigel Crawford 4. BRMS1 Douglas R. Hurst, Christa Manton and Danny R. Welch 5. Immune regulation of metastasis Brian Ruffell6. microRNA and metastasis Li Ma7. Different mechanisms of tumor migration Peter Friedl8. Cytokine regulation of metastasis/tumorigenicity Nikki Cheng

Reseñas

Praise for the Serial: "This classic and essential series presents critical overviews on select aspects of both cancer research and the basic underlying sciences."—American Scientist"Excellent, highly informative, in-depth reviews…expertly written, up-to-date, and well-referenced."—Journal of Medicinal Chemistry"This is a series that has a long tradition of excellence in the field of cancer biology." —Doody’s Publishing Reviews

Detalles del producto

  • Edición: 1
  • Última edición
  • Volumen: 132
  • Publicado: 5 de septiembre de 2016
  • Idioma: Inglés

Sobre los editores

DW

Danny R Welch

University of Kansas Cancer Center, USA
Afiliaciones y experiencia
University of Kansas Cancer Center, USA

PF

Paul B. Fisher

Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).
Afiliaciones y experiencia
Department of Cellular, Molecular and Genetic Medicine, VCU Institute of Molecular Medicine, VCU Massey Comprehensive Cancer Center, Virginia Commonwealth University, School of Medicine, Virginia, United States

Ver libro en ScienceDirect

Lee Molecular and Cellular Basis of Metastasis: Road to Therapy en ScienceDirect